Advaxis, Inc. (ADXS) Reaches $3.00 52 Week Low; Loews Lowered Its Kinross Gold (KGC) Position

November 14, 2017 - By Linda Rogers

The stock of Advaxis, Inc. (NASDAQ:ADXS) hit a new 52-week low and has $2.91 target or 3.00% below today’s $3.00 share price. The 6 months bearish chart indicates high risk for the $123.20M company. The 1-year low was reported on Nov, 14 by Barchart.com. If the $2.91 price target is reached, the company will be worth $3.70M less. About 196,453 shares traded. Advaxis, Inc. (NASDAQ:ADXS) has risen 11.01% since November 14, 2016 and is uptrending. It has underperformed by 5.69% the S&P500.

Loews Corp decreased Kinross Gold Corp (KGC) stake by 30.2% reported in 2017Q2 SEC filing. Loews Corp sold 478,240 shares as Kinross Gold Corp (KGC)’s stock rose 9.54%. The Loews Corp holds 1.11M shares with $4.49M value, down from 1.58M last quarter. Kinross Gold Corp now has $5.36 billion valuation. The stock declined 0.23% or $0.01 reaching $4.31 per share. About 1.97M shares traded. Kinross Gold Corporation (USA) (NYSE:KGC) has declined 13.79% since November 14, 2016 and is downtrending. It has underperformed by 30.49% the S&P500.

Among 17 analysts covering Kinross Gold Corporation (NYSE:KGC), 8 have Buy rating, 0 Sell and 9 Hold. Therefore 47% are positive. Kinross Gold Corporation had 59 analyst reports since July 24, 2015 according to SRatingsIntel. BMO Capital Markets maintained Kinross Gold Corporation (USA) (NYSE:KGC) rating on Monday, September 18. BMO Capital Markets has “Buy” rating and $5.25 target. The firm has “Equal Weight” rating by Barclays Capital given on Friday, February 12. Credit Suisse maintained the stock with “Outperform” rating in Thursday, March 31 report. RBC Capital Markets maintained Kinross Gold Corporation (USA) (NYSE:KGC) rating on Monday, October 30. RBC Capital Markets has “Buy” rating and $5.25 target. The firm has “Outperform” rating given on Monday, March 7 by BMO Capital Markets. Goldman Sachs upgraded Kinross Gold Corporation (USA) (NYSE:KGC) on Wednesday, May 11 to “Neutral” rating. Macquarie Research upgraded the shares of KGC in report on Friday, July 1 to “Neutral” rating. The firm has “Buy” rating given on Thursday, October 19 by TD Securities. On Friday, July 14 the stock rating was maintained by Jefferies with “Hold”. The firm earned “Outperform” rating on Monday, February 8 by BMO Capital Markets.

Analysts await Kinross Gold Corporation (USA) (NYSE:KGC) to report earnings on February, 21. They expect $0.04 EPS, up 200.00% or $0.08 from last year’s $-0.04 per share. KGC’s profit will be $49.74M for 26.94 P/E if the $0.04 EPS becomes a reality. After $0.07 actual EPS reported by Kinross Gold Corporation (USA) for the previous quarter, Wall Street now forecasts -42.86% negative EPS growth.

Loews Corp increased Carmax Inc (NYSE:KMX) stake by 20,000 shares to 116,000 valued at $7.32 million in 2017Q2. It also upped Goldcorp Inc (NYSE:GG) stake by 716,210 shares and now owns 816,210 shares. Cloud Peak Energy Inc (NYSE:CLD) was raised too.

Analysts await Advaxis, Inc. (NASDAQ:ADXS) to report earnings on January, 8. After $-0.80 actual EPS reported by Advaxis, Inc. for the previous quarter, Wall Street now forecasts -46.25% EPS growth.

Advaxis, Inc. is a clinical-stage biotechnology firm focused on the discovery, development and commercialization of Listeria monocytogenes -Listeriolysin O (LLO) cancer immunotherapies. The company has market cap of $123.20 million. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. It currently has negative earnings. These Lm-LLO strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com